Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
RationaleThere is no consensus as to when treatment for idiopathic pulmonary fibrosis (IPF) should be initiated. Some physicians prefer not to treat patients with preserved lung volume.ObjectiveTo investigate whether patients with IPF and preserved lung volume receive the same benefit from nintedanib as patients with more impaired lung volume.Metho...
Alternative Titles
Full title
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5520269
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5520269
Other Identifiers
ISSN
0040-6376
E-ISSN
1468-3296
DOI
10.1136/thoraxjnl-2016-208710
